Paulo Lilaia, president of the board of APOGEN and CEO of Generis, highlights the need for generics in the healthcare system and the government’s approach to their implementation. He also discusses the introduction of biosimilars into the Portuguese healthcare system and the cost-saving effect this has for patients and companies, which paves the way for new investments.
The goal of the Portuguese government a few years back was that generics would account for 53 percent of the market share in 2018. Where do we stand today with this goal?
" In general, we are moving in the right direction, and now that professionals are made more and more aware; biosimilars will be another success story for Portugal’s health care system."
